- Home
- NGNE vs OPFI Comparison
NGNE vs OPFI Comparison
Compare NGNE & OPFI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NGNE
- OPFI
- Stock Information
- Founded
- NGNE 2003
- OPFI 2009
- Country
- NGNE United States
- OPFI United States
- Employees
- NGNE N/A
- OPFI N/A
- Industry
- NGNE Biotechnology: Pharmaceutical Preparations
- OPFI Finance: Consumer Services
- Sector
- NGNE Health Care
- OPFI Finance
- Exchange
- NGNE Nasdaq
- OPFI Nasdaq
- Market Cap
- NGNE 325.3M
- OPFI 300.3M
- IPO Year
- NGNE N/A
- OPFI N/A
- Fundamental
- Price
- NGNE $18.48
- OPFI $10.17
- Analyst Decision
- NGNE Strong Buy
- OPFI Buy
- Analyst Count
- NGNE 7
- OPFI 2
- Target Price
- NGNE $41.86
- OPFI $11.75
- AVG Volume (30 Days)
- NGNE 110.1K
- OPFI 1.3M
- Earning Date
- NGNE 08-11-2025
- OPFI 08-06-2025
- Dividend Yield
- NGNE N/A
- OPFI 9.79%
- EPS Growth
- NGNE N/A
- OPFI N/A
- EPS
- NGNE N/A
- OPFI N/A
- Revenue
- NGNE N/A
- OPFI $320,831,000.00
- Revenue This Year
- NGNE N/A
- OPFI $116.69
- Revenue Next Year
- NGNE N/A
- OPFI $9.90
- P/E Ratio
- NGNE N/A
- OPFI N/A
- Revenue Growth
- NGNE N/A
- OPFI 31.26
- 52 Week Low
- NGNE $6.88
- OPFI $3.93
- 52 Week High
- NGNE $74.49
- OPFI $17.73
- Technical
- Relative Strength Index (RSI)
- NGNE 35.93
- OPFI 46.36
- Support Level
- NGNE $19.59
- OPFI $10.11
- Resistance Level
- NGNE $20.46
- OPFI $10.76
- Average True Range (ATR)
- NGNE 1.23
- OPFI 0.47
- MACD
- NGNE -0.20
- OPFI 0.08
- Stochastic Oscillator
- NGNE 13.37
- OPFI 51.49
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
About OPFI OppFi Inc.
OppFi Inc is a tech-enabled, mission-driven specialty finance platform that broadens the reach of community banks to extend credit access to everyday Americans. It recognizes revenue through finance charges on installment and SalaryTap contracts based on the interest method.